DiaMedica Therapeutics is a clinical-stage biotechnology company developing synthetic human proteins to treat serious conditions caused by restricted blood flow, such as strokes and kidney disease. The company's primary focus is on advancing its lead drug candidate through late-stage medical trials for multiple indications. I have synthesized my analysis of its core fundamentals, live market action, and peer metrics to provide a comprehensive thesis. What specific areas can I detail for you?
